Department of Nephrology, Dialysis and Transplantation, Departmental Hospital of Vendée, La Roche-sur-Yon, France.
Centre de Recherche en Transplantation et Immunologie INSERM UMR1064, Université de Nantes, Centre Hospitalier Universitaire de Nantes, RTRS "Centaure", Nantes, France.
Nephrol Dial Transplant. 2019 Apr 1;34(4):703-711. doi: 10.1093/ndt/gfy221.
The clinical utility of screening biopsies (SBs) at 1 year post-transplantation is still debated, especially for stable kidney graft recipients. Given the heterogeneity in practices between transplantation centres, the objective of this study was to compare graft and patient survival of stable patients according to whether they were followed up in a transplantation centre with or without a policy for having an SB at 1 year post-transplantation.
From a French multicentre cohort, we studied 1573 kidney recipients who were alive with stable graft function at 1 year post-transplantation, with no acute rejection in their first year post-transplantation.
Using propensity score-based analyses, we did not observe any significant difference in the relative risk for graft failure between patients from centres with a 1-year SB policy and those from other centres [hazard ratio = 1.15, 95% confidence interval (CI) 0.86-1.53]. The corresponding adjusted survival probability at 8 years post-transplantation was 69% (95% CI 61-74%) for patients from centres with a 1-year SB policy versus 74% (95% CI 67-79%) for those from other centres.
A 1-year SB policy for stable patients may not lead to therapeutical benefits for improved graft and patient survival. Further studies examining the benefits versus the risks of a 1-year SB policy are warranted to demonstrate the long-term utility of this intervention.
移植后 1 年进行筛查活检(SB)的临床实用性仍存在争议,尤其是对于稳定的肾移植受者。鉴于移植中心之间实践的异质性,本研究的目的是比较稳定患者的移植物和患者存活率,根据他们是否在有或没有 1 年后 SB 政策的移植中心接受随访。
从法国多中心队列中,我们研究了 1573 名在移植后 1 年时存活且移植物功能稳定、移植后第 1 年无急性排斥反应的肾移植受者。
使用倾向评分匹配分析,我们未观察到有 SB 政策的中心和其他中心的患者之间移植失败的相对风险有任何显著差异[风险比=1.15,95%置信区间(CI)0.86-1.53]。调整后 8 年后的移植存活率为有 SB 政策的中心的患者为 69%(95%CI 61-74%),而其他中心的患者为 74%(95%CI 67-79%)。
对于稳定的患者,1 年后 SB 政策可能不会带来改善移植物和患者存活率的治疗益处。需要进一步研究以检查 1 年后 SB 政策的益处与风险,以证明这种干预的长期效用。